Emmaus Life Sciences Inc represents values of innovation, integrity, and commitment to improving patient lives. With a focus on developing and commercializing innovative treatments, the company is dedicated to addressing unmet medical needs. Emmaus Life Sciences Inc prioritizes scientific excellence and collaboration to advance medical research. By embracing a patient-centric approach, the company aims to provide accessible and effective therapies. Through their dedication to improving healthcare outcomes, Emmaus Life Sciences Inc strives to make a positive impact on the lives of individuals worldwide.

Emmaus Life Sciences Inc is primarily present in the United States.

Emmaus Life Sciences Inc has achieved several significant milestones. One key accomplishment is the approval of their product, Endari, by the U.S. Food and Drug Administration (FDA) in 2017. Endari is an innovative treatment for sickle cell disease, providing a much-needed option for patients. Additionally, Emmaus has successfully established partnerships and collaborations with leading healthcare organizations to advance research and development efforts. The company has also expanded its global presence, obtaining regulatory approvals for Endari in several countries. These achievements demonstrate Emmaus Life Sciences Inc's commitment to improving the lives of individuals affected by sickle cell disease and solidify its position as a key player in the pharmaceutical industry.

Emmaus Life Sciences Inc. is a company specializing in the development and commercialization of innovative treatments for rare and orphan diseases. Founded in 2000, Emmaus has a strong focus on improving patient outcomes and quality of life through groundbreaking therapies. The company's flagship product, Endari, is an FDA-approved treatment for sickle cell disease, offering patients a promising alternative to manage the symptoms and complications associated with this condition. Emmaus Life Sciences Inc. is committed to advancing medical solutions for underserved patient populations and continues to expand its portfolio of cutting-edge therapies.

The main competitors of Emmaus Life Sciences Inc in the market include pharmaceutical companies such as Amgen, Novartis, and Roche.

Emmaus Life Sciences Inc primarily operates in the pharmaceutical industry.

The business model of Emmaus Life Sciences Inc. focuses on developing and commercializing innovative treatments for rare and orphan diseases. They specialize in the research and development of pharmaceutical products, with a particular emphasis on sickle cell disease and other hematologic disorders. Emmaus Life Sciences Inc. aims to provide patients with safe and effective therapies that improve their quality of life. Through strategic partnerships and collaborations, they strive to advance scientific knowledge and provide innovative solutions for unmet medical needs. The company's dedication to addressing rare diseases showcases their commitment to making a positive impact on patients' lives.

Razmerje cena/dobiček Emmaus Life Sciences je 0,05.

Koeficient Emmaus Life Sciences cene in prihodkov je 0,01.

AlleAktien kakovostni rezultat za Emmaus Life Sciences je 6/10.

pričakovana Emmaus Life Sciences promet je 21,73 mio. USD.

Dobiček pričakovana Emmaus Life Sciences je 2,52 mio. USD.

The Emmaus Life Sciences Inc. is a pharmaceutical company specializing in the development and marketing of products for the treatment of rare diseases. The company's business model is based on identifying medical needs that are often ignored by large pharmaceutical companies due to their rarity. The company specializes in the production and marketing of products for the treatment of rare blood diseases, particularly sickle cell anemia. Emmaus is dedicated to improving the quality of life for people with rare diseases by offering medical solutions that not only alleviate symptoms but also improve the underlying condition. Emmaus has developed the first and only FDA-approved medication for the treatment of sickle cell anemia, known as Endari. This medication has been designated as an orphan drug due to its development for a rare disease and the high medical need for it. In addition to Endari, Emmaus has also developed another medication for the treatment of cancer-induced anemia, which is sold under the name NutreStore. This medication has also been approved as an orphan drug and is currently distributed by Emmaus in the USA and internationally. Emmaus also offers various services to support patients affected by sickle cell anemia and other rare diseases. These services include patient support programs, financial solutions, education, and counseling to help patients improve their health. Emmaus' business model also involves building partnerships to meet the medical needs of patients with rare diseases. The company collaborates with research institutions, government agencies, and other companies to pool resources and expertise and develop innovative solutions together. Emmaus is an international company operating in various sectors worldwide. The company is headquartered in Torrance, California, and has a presence in the USA, Europe, and Asia. Emmaus is listed on NASDAQ and has become a key player in the field of rare diseases. In summary, the business model of Emmaus Life Sciences Inc. is based on the development and marketing of products for the treatment of rare diseases. The company specializes in sickle cell anemia and also offers various services to support patients. Emmaus partners with different organizations to identify medical needs and develop innovative solutions together to improve the lives of people with rare diseases.

Emmaus Life Sciences izplača dividendo v višini 0 USD, razdeljeno na izplačil letno.

Dividende za Emmaus Life Sciences trenutno ni mogoče izračunati ali pa podjetje ne izplačuje dividend.

ISIN od Emmaus Life Sciences je US29137T1016.

WKN od Emmaus Life Sciences je A2PNWG.

Oznaka delnice Emmaus Life Sciences je EMMA.

V zadnjih 12 mesecih je Emmaus Life Sciences izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Emmaus Life Sciences predvidoma izplačal dividendo v višini 0 USD.

Trenutni donos od dividend za Emmaus Life Sciences znaša .

Emmaus Life Sciences izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Emmaus Life Sciences je v zadnjih 0 letih vsako leto izplačeval dividend.

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

Emmaus Life Sciences je razvrščen v sektor 'Zdravje'.

Da si prejel zadnjo dividendo Emmaus Life Sciences z dne 7. 8. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 7. 8. 2024.

Zadnje izplačilo dividende je bilo 7. 8. 2024.

V letu 2023 je Emmaus Life Sciences 0 USD izplačal kot dividende.

Dividende od Emmaus Life Sciences se izplačujejo v USD.